Hospital-Integrated Tumor Biobank, Pasteur Hospital, Nice, France,
Virchows Arch. 2014 Jan;464(1):3-9. doi: 10.1007/s00428-013-1524-z. Epub 2013 Dec 14.
Access to human bioresources is essential to the understanding of human diseases and to the discovery of new biomarkers aimed at improving the diagnosis, prognosis, and the predictive response of patients to treatments. The use of biospecimens is strictly controlled by ethical assessment, which complies with the laws of the country. These laws regulate the partnerships between the biobanks and industrial actors. However, private-public partnerships (PPP) can be limiting for several reasons, which can hamper the discovery of new biological tests and new active molecules targeted to human diseases. The bottlenecks and roadblocks in establishing these partnerships include: poor organization of the biobank in setting up PPP, evaluation of the cost of human samples, the absence of experience on the public side in setting up contracts with industry, and the fact that public and private partners may not share the same objectives. However, it is critical, in particular for academic biobanks, to establish strong PPP to accelerate translational research for the benefits of patients, and to allow the sustainability of the biobank. The purpose of this review is to discuss the main bottlenecks and roadblocks that can hamper the establishment of PPP based on solid and trusting relationships.
生物资源的获取对于理解人类疾病以及发现新的生物标志物至关重要，这些标志物旨在改善患者的诊断、预后和对治疗的预测反应。生物样本的使用受到严格的伦理评估控制，符合国家法律的规定。这些法律规范了生物库与工业参与者之间的合作关系。然而，公私合作伙伴关系（PPP）可能会因为以下几个原因而受到限制，这可能会阻碍新的生物测试和针对人类疾病的新活性分子的发现。在建立这些合作伙伴关系时存在的瓶颈和障碍包括：生物库在建立 PPP 方面组织不善、评估人类样本的成本、公共部门在与工业界签订合同方面缺乏经验，以及公共和私营合作伙伴可能没有共同的目标。然而，建立强大的公私合作伙伴关系对于学术生物库来说至关重要，这可以加速转化研究，使患者受益，并确保生物库的可持续性。本文的目的是讨论可能会阻碍基于稳固和值得信赖的关系建立公私合作伙伴关系的主要瓶颈和障碍。
